Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 101–200 of 1,000

Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy
Shenwu Zhang, Jing Wang, Zhiqiang Kong, Xinxin Sun, Zhonggui He, Bingjun Sun, Cong Luo, Jin Sun · 2022 · Biomaterials
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, Connie P.M. Duong, Miles Cameron Andrews, Loïc Verlingue, Gladys Ferrere, Sonia Becharef, Marie Vétizou, Romain Daillère et al. · 2019 · Cell Research
Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy
Masoud Delfi, Rossella Sartorius, Milad Ashrafizadeh, Esmaeel Sharifi, Yapei Zhang, Piergiuseppe De Berardinis, Ali Zarrabi, Rajender S. Varma, Franklin R. Tay, Bryan Ronain Smith et al. · 2021 · Nano Today
Clinical cancer immunotherapy: Current progress and prospects
Chenglong Liu, Mengxuan Yang, Daizhou Zhang, Ming Chen, Di Zhu · 2022 · Frontiers in Immunology
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
Duaa O. Khair, Heather J. Bax, Silvia Mele, Silvia Crescioli, Giulia Pellizzari, Atousa Khiabany, Mano Nakamura, R. J. C. Harris, Elise French, Ricarda M. Hoffmann et al. · 2019 · Frontiers in Immunology
New B7 Family Checkpoints in Human Cancers
Ling Ni, Chen Dong · 2017 · Molecular Cancer Therapeutics
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio et al. · 2019 · The Journal of Experimental Medicine
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du, Min Yang, Abbey Turner, Chunling Xu, Robert Louis Ferris, Jian‐An Huang, Larry Kane, Binfeng Lu · 2017 · International Journal of Molecular Sciences
Cancer immunotherapy: broadening the scope of targetable tumours
Jitske van den Bulk, Els M.E. Verdegaal, Noel F.C.C. de Miranda · 2018 · Open Biology
Immune checkpoints in the tumor microenvironment
Salman M. Toor, Varun Sasidharan Nair, Julie V. Decock, Eyad Elkord · 2019 · Seminars in Cancer Biology
Hallmarks of response to immune checkpoint blockade
Alexandria P. Cogdill, Miles Cameron Andrews, Jennifer Ann Wargo · 2017 · British Journal of Cancer
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Alexandra M. Hoyt-Miggelbrink, Joshua D. Jackson, Selena Lorrey, Ethan S. Srinivasan, Jessica Waibl Polania, Daniel S. Wilkinson, Peter Edward Fecci · 2021 · Clinical Cancer Research
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N. · 2021 · Journal of Clinical Investigation
Treg-mediated acquired resistance to immune checkpoint inhibitors
Reem Saleh, Eyad Elkord · 2019 · Cancer Letters
TIM-3, a promising target for cancer immunotherapy
He, Yayi, Cao, Jie, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred · 2018 · OncoTargets and Therapy
The cutting-edge progress of immune-checkpoint blockade in lung cancer
Fei Zhou, Meng Qiao, Caicun Zhou · 2020 · Cellular and Molecular Immunology
Role of Galectins in Tumors and in Clinical Immunotherapy
Feng‐Cheng Chou, Heng-Yi Chen, Chih-Chi Kuo, Huey‐Kang Sytwu · 2018 · International Journal of Molecular Sciences
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Deng, Jie, Li, Jiannan, Sarde, Aurelien, Lines, J. Louise, Lee, Yu-Chi, Qian, David C., Pechenick, Dov A., Manivanh, Richard, Le Mercier, Isabelle, Lowrey, Christopher H. et al. · 2019 · Cancer Immunology Research
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
In-Young Jung, Yoon-Young Kim, Ho-Sung Yu, Myoungsoo Lee, Seokjoong Kim, Jung‐Min Lee · 2018 · Cancer Research
RETRACTED ARTICLE: Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
Yuying Liu, Xiaoyu Liang, Xiaonan Yin, Jiadi Lv, Ke Tang, Jingwei Ma, Tiantian Ji, Huafeng Zhang, Wenqian Dong, Xun Jin et al. · 2017 · Nature Communications · Retracted
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Prabhakaran Kumar, Palash Bhattacharya, Bellur S. Prabhakar · 2018 · Journal of Autoimmunity
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, Chong Kim · 2018 · International Journal of Molecular Sciences
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam Jacob Schoenfeld, Darwin Ye, George J. Fromm, Hira A. Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu et al. · 2024 · Cancer Cell
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Aleksandra Popović, Elizabeth M. Jaffee, Neeha Zaidi · 2018 · Journal of Clinical Investigation
Emerging role of PTEN loss in evasion of the immune response to tumours
Thiago Vidotto, Camila Morais Melo, Erick C. Castelli, Madhuri Koti, Rodolfo Borges dos Reis, Jeremy Andrew Squire · 2020 · British Journal of Cancer
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Yiting Wang, Huanbin Wang, Han Yao, Chushu Li, Jing‐Yuan Fang, Jie Xu · 2018 · Frontiers in Pharmacology
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Peijie Wu, Wei Qiang Gao, Miao Su, Edouard Collins Nice, Wenhui Zhang, Jie Lin, Na Xie · 2021 · Frontiers in Cell and Developmental Biology
Cancer immunotherapy: it’s time to better predict patients’ response
Charlotte Pilard, Marie Ancion, Philippe Delvenne, Guy Jérusalem, Pascale Hubert, Michael F. Herfs · 2021 · British Journal of Cancer
Bispecific antibodies in cancer immunotherapy
Eva Dahlén, Niina Veitonmäki, Per Norlén · 2018 · Therapeutic Advances in Vaccines and Immunotherapy
In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer
Zeyu Chen, Eri Arai, Omar Khan, Zhen Zhang, Shin Foong Ngiow, Yuan Ming He, Hua Huang, Sasikanth Manne, Zhendong Cao, Amy E. Baxter et al. · 2021 · Cell
If we build it they will come: targeting the immune response to breast cancer
Margaret Elena Gatti-Mays, Justin Micah Balko, Sofia R. Gameiro, Harry D. Bear, Sangeetha Prabhakaran, Jami Aya Fukui, Mary Lenora Disis, Rita Nanda, James L. Gulley, Kevin M. Kalinsky et al. · 2019 · npj Breast Cancer
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo, Hua Jiang, Bizhi Shi, Min Zhou, Honghong Zhang, Zhimin Shi, Guoxiu Du, Hong Luo, Xiuqi Wu, Yi Wang et al. · 2018 · Frontiers in Pharmacology
Immunotherapy for glioblastoma: the promise of combination strategies
Mathilde Bausart, Véronique Préat A, Alessio Malfanti · 2022 · Journal of Experimental & Clinical Cancer Research
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Rossana Franzin, Giuseppe Stefano Netti, Federica Spadaccino, Camillo Porta, Loreto Gesualdo, Giovanni Stallone, Giuseppe Castellano, Elena Ranieri · 2020 · Frontiers in Immunology
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou, Noushin Niknafs, Kristen Ashley Marrone, Daniel C. Bruhm, James Robert White, Jarushka Naidoo, Karlijn Hummelink, Kim Monkhorst, Ferry Lalezari, Mara R. Lanis et al. · 2020 · Nature Cancer
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su, Jiali Yang · 2018 · Journal of Immunology Research
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
Esra A. Akbay, Shohei Koyama, Yan Liu, Ruben Dries, Lauren E. Bufe, Michael Silkes, Md Maksudul Alam, Dillon M. Magee, Robert E. Jones, Masahisa Jinushi et al. · 2017 · Journal of Thoracic Oncology
Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
Jeffrey Yang, Longqin Hu · 2018 · Medicinal Research Reviews
Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
Xi Chen, Xiaohui Pan, Wenxin Zhang, Hongjie Guo, Shuyuan Cheng, Qiaojun He, Bo Yang, Ling Ding · 2019 · Acta Pharmaceutica Sinica B
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora, Rodion A. Velichinskii, Randy W. Lesh, Usman Ali, Michal Jakub Kubiak, Pranshu Bansal, Hossein Borghaei, Martin Joseph Edelman, Yanis Boumber · 2019 · Advances in Therapy
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu · 2020 · Cancer Medicine
Immune Resistance in Lung Adenocarcinoma
Μάγδα Σπέλλα, Georgios T. Stathopoulos · 2021 · Cancers
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
Tumor Evolution as a Therapeutic Target
Nabil Amirouchene-Angelozzi, Charles Swanton, Alberto Bardelli · 2017 · Cancer Discovery
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
Zheng Wang, Chuanbao Zhang, Xing Liu, Zhiliang Wang, Lihua Sun, Guanzhang Li, Jingshan Liang, Huimin Hu, Yanwei Liu, Wei Zhang et al. · 2016 · OncoImmunology
Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells
Laia Gorchs, Carlos Fernández Moro, Peter Bankhead, Katharina P. Kern, Imrul Sadeak, Qingda Meng, Elena B. Rangelova, Helen Kaipe · 2019 · Frontiers in Immunology
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Tae Kon Kim, Roy S. Herbst, Lieping Chen · 2018 · Trends in Immunology
Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
Robert D. Leone, Im-Meng Sun, Min Hee Oh, Im‐Hong Sun, Jiayu Wen, Judson M. Englert, Jonathan D. Powell · 2018 · Cancer Immunology Immunotherapy
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu, Lisa A. Kottschade, Andrea Forschner, Ralf Gutzmer, Max S. Schlaak, Lucie Heinzerling, Angela M. Krackhardt, Carmen Loquai et al. · 2017 · European Journal of Cancer
Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, Hai‐Kui Yang, Jia-Mei Dong, Zhi-Hua Xiao, Xin He, Jiahao Guo, Ruiqi L. Wang, Bo Dai et al. · 2024 · Biomedicine & Pharmacotherapy
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn, Sudha Rao · 2017 · Molecular Immunology
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, Parsa Modareszadeh, Eranda Berisha, Parinaz Sadat Alemi, Maria del Carmen Chacon Castro, Alexander R. Deese, Zhang Li · 2022 · Cancers
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Yoshiyuki Nakamura · 2019 · Frontiers in Medicine
Immunotherapy for Glioblastoma: Current Progress and Challenges
Miranda W. Yu, Daniela F. Quail · 2021 · Frontiers in Immunology
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, Ming, Yu, Shengnan, Qin, Shuang, Liu, Qian, Xu, Hanxiao, Zhao, Weiheng, Chu, Qian, Wu, Kongming · 2018 · Journal of Hematology & Oncology
Mechanisms of immune escape in the cancer immune cycle
Sha Tang, Qian Ning, Ling Yang, Zhongcheng Mo, Shengsong Tang · 2020 · International Immunopharmacology
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
David A. Braun, Kelly P. Burke, Eliezer M. Van Allen · 2016 · Clinical Cancer Research
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Chunwan Lu, Asif M. Talukder, Natasha M. Savage, Nagendra Singh, Kebin Liu · 2017 · OncoImmunology
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
Xin Chen, Xiaomin Song, Kang Li, Tong Zhang · 2019 · Frontiers in Immunology
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Zhi-Yong Wang, Victoria H. Wu, M. Allevato, M. Gilardi, Yudou He, Juan Luis Callejas-Valera, L. Vitale-Cross, Daniel Martin, Panomwat Amornphimoltham, J. Mcdermott et al. · 2019 · Nature Communications
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
Laetitia Seguin, Manon Durandy, Chloé C. Féral · 2022 · Cancers
Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion
Jessica Waibl Polania, Alexandra M. Hoyt-Miggelbrink, William H. Tomaszewski, Lucas P. Wachsmuth, Selena Lorrey, Daniel S. Wilkinson, Emily Lerner, Karolina I. Woroniecka, John B. Finlay, Katayoun Ayasoufi et al. · 2024 · Immunity
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlašić, Sebastian Oberbeck et al. · 2018 · Cancer Research
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, Anshika, Tiek, Deanna, Song, Xiao, Huang, Tianzhi, Hu, Bo, Cheng, Shi-Yuan · 2021 · Cells
Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
Lyndsay Avery, Jessica N. Filderman, Andrea L. Szymczak-Workman, Larry Kane · 2018 · Proceedings of the National Academy of Sciences
Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment
Guanxi Qiao, Minhui Chen, Hemn Mohammadpour, Cameron R. MacDonald, Mark J. Bucsek, Bonnie Lee Hylander, Joseph J. Barbi, Elizabeth A. Repasky · 2021 · Cancer Immunology Research
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott N. Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn et al. · 2020 · Journal of Thoracic Oncology
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
Bo Wu, Xiang Shi, Meixi Jiang, Hongxu Liu · 2023 · Molecular Cancer
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda et al. · 2018 · Clinical Cancer Research
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Sashi Kandel, Pratik Adhikary, Guangfu Li, Kun Cheng · 2021 · Cancer Letters
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas Buckner Johnson, Mellissa J. Nixon, Yu Wang, Daniel Y. Wang, Emily H. Castellanos, Monica Valeria Estrada, Paula I. González Ericsson, Candace H. Cote, Roberto Salgado, Violeta M. Sanchez et al. · 2018 · JCI Insight
Pseudoprogression and hyperprogression after checkpoint blockade
Qiaohong Wang, Jingze Gao, Xia Wu · 2018 · International Immunopharmacology
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha Rani Talapati et al. · 2021 · Communications Biology
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
Ludmila Danilova, Hao Wang, Joel Chaim Sunshine, Genevieve J. Kaunitz, Tricia R. Cottrell, Haiying Xu, Jessica Esandrio, Robert A. Anders, Leslie Cope, Drew M. Pardoll et al. · 2016 · Proceedings of the National Academy of Sciences
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
Akinori Sasaki, Yoshiaki Nakamura, Saori Mishima, Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino et al. · 2019 · Gastric Cancer
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Harding, James J., Moreno, Victor, Bang, Yung-Jue, Hong, Min Hee, Patnaik, Amita, Trigo, José, Szpurka, Anna M., Yamamoto, Noboru, Doi, Toshihiko, Fu, Siqing et al. · 2021 · Clinical Cancer Research
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Matias Ilmari Autio, Suvi‐Katri Leivonen, Oscar E. Brück, Satu M. Mustjoki, Judit Meszaros Jørgensen, Marja‐Liisa Karjalainen‐Lindsberg, Klaus Beiske, Harald Holte, Teijo S. Pellinen, Sirpa Leppä · 2020 · Haematologica
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han, Jing Nie · 2017 · Oncotarget
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
Wenbo Yao, Qian Ba, Xiaoguang Li, Hui‐Liang Li, Shoude Zhang, Ya Yuan, Feng Wang, Xiaohua Duan, Jingquan Li, Weidong Zhang et al. · 2017 · EBioMedicine
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Jihane Boustani, M. Grapin, Pierre-Antoine Laurent, Lionel Apétoh, Céline Mirjolet · 2019 · Cancers
Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance
Ruihan Tang, Manu Rangachari, Vijay Kumar Kuchroo · 2019 · Seminars in Immunology
Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy
Ajaz Ahmad Bhat, Parvaiz Yousuf, Nissar Ahmad Wani, Arshi Rizwan, Shyam Singh Chauhan, Mushtaq Ahmad Siddiqi, Davide Bedognetti, Wael M. El-Rifai, Michael Paul Frenneaux, Surinder K. Batra et al. · 2021 · Signal Transduction and Targeted Therapy
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Antonino Glaviano, Hannah Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina, Donavan Jia Jie Tan, Wency Tan, Hui Li Ang, Daniela Carbone et al. · 2025 · Journal of Hematology & Oncology
A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD‐1/PD‐L1 Axis
Mei‐Zhen Zou, Wenlong Liu, Chu‐Xin Li, Diwei Zheng, Jin‐Yue Zeng, Fan Gao, Jing‐Jie Ye, Xian‐Zheng Zhang · 2018 · Small
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Katsiaryna Marhelava, Zofia Pilch, Małgorzata Bajor, Agnieszka Graczyk‐Jarzynka, Radosław Zagożdżon · 2019 · Cancers
Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
Timm Hoeres, Manfred Smetak, Dominik Pretscher, Martin Wilhelm · 2018 · Frontiers in Immunology
The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
Su Yin Lim, Elena Shklovskaya, Jenny Lee, Bernadette Pedersen, Ashleigh Stewart, Zizhen Ming, Mal Irvine, Brindha Shivalingam, Robyn P.M. Saw, Alexander Maxwell Menzies et al. · 2023 · Nature Communications
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. Fréderique de Graaf, Lisanne de Vor, Ron A. M. Fouchier, Bernadette G. van den Hoogen · 2018 · Cytokine & Growth Factor Reviews
Immunotherapy for gastric cancer: dilemmas and prospect
Zhao Qingfang, Liang Cao, Lulu Guan, Liangyu Bie, Saiqi Wang, Bojian Xie, Xiaobing Chen, Xiaokun Shen, Fei-Ling Cao · 2018 · Briefings in Functional Genomics
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Qiaohong Wang, Xia Wu · 2017 · International Immunopharmacology
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
Aohan Hou, Kaiyu Hou, Qiubo Huang, Yujie Lei, Wan-Ling Chen · 2020 · Frontiers in Immunology
Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection
Marcia Bellon, Christophe Nicot · 2017 · Viruses
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley, Peter Parham, Jeffrey S. Miller · 2018 · Blood
Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer Immunotherapy
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou · 2021 · Advanced Materials
Cancer Immunoediting in the Era of Immuno-oncology
Matthew M. Gubin, Matthew D. Vesely · 2022 · Clinical Cancer Research
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
Wong, Jeffrey Sum Lung, Kwok, Gerry Gin Wai, Tang, Vikki, Li, Bryan Cho Wing, Leung, Roland, Chiu, Joanne, Ma, Ka Wing, She, Wong Hoi, Tsang, Josephine, Lo, Chung Mau et al. · 2021 · Journal for ImmunoTherapy of Cancer
Novel targets for immune-checkpoint inhibition in cancer
Maxime Borgeaud, José Luís Sandoval, Michel Obéid, Giuseppe Luigi Banna, Olivier Alain Michielin, Alfredo Addeo, Alex Friedlaender · 2023 · Cancer Treatment Reviews
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Pai, Chien-Chun Steven, Huang, John T., Lu, Xiaoqing, Simons, Donald M., Park, Chanhyuk, Chang, Anthony, Tamaki, Whitney, Liu, Eric, Roybal, Kole T., Seagal, Jane et al. · 2019 · Immunity